ATOS - Atossa Genetics Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.57
+0.07 (+2.80%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close2.50
Open2.53
Bid2.52 x 1400
Ask2.73 x 1100
Day's Range2.50 - 2.60
52 Week Range2.01 - 19.08
Volume96,418
Avg. Volume393,752
Market Cap7.235M
Beta4.06
PE Ratio (TTM)N/A
EPS (TTM)-6.97
Earnings DateAug 13, 2018 - Aug 17, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.00
Trade prices are not sourced from all markets
  • GlobeNewswire3 days ago

    Atossa Genetics Opens Enrollment in Phase 2 Study of Oral Endoxifen to Treat Breast Cancer

    Atossa Genetics Inc. (ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that it has opened a Phase 2 study of its proprietary oral Endoxifen to treat breast cancer in the “window of opportunity” setting, which is the period between diagnosis of breast cancer and surgery. “Once a patient is diagnosed with breast cancer, there is a window of time, typically a number of weeks, before definitive surgery is performed,” commented Steve Quay, Ph.D., MD, President and CEO of Atossa. “Our goal with this study is to show that our proprietary oral Endoxifen can modify the cancer activity in estrogen-receptor-positive patients during this ‘window of opportunity.' Tamoxifen, the current standard of care, has not been effective in this setting, probably because it can take 50-200 days to reach steady-state of Endoxifen blood levels, while the surgery is usually completed within 30 to 45 days of diagnosis.

  • ACCESSWIRE19 days ago

    ''Strong Economy, Trade Wars & Market Volatility''

    SAN FRANCISCO, CA / ACCESSWIRE / June 27, 2018 / Vista Partners ("Vista") has published June's FREE Macroeconomic & Investment Monthly Newsletter, "Strong Economy, Trade Wars & Market Volatility." ...

  • GlobeNewswire20 days ago

    Atossa Genetics Opens Its Phase 2 Study of Topical Endoxifen to Treat Mammographic Breast Density

    Atossa Genetics Inc. (ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that it has opened its Phase 2 study of proprietary topical Endoxifen on mammographic breast density, or MBD, reduction. Studies by others have shown that a reduction in MBD reduces the risk of developing breast cancer and may potentially improve the accuracy of mammography in finding cancer.

  • GlobeNewswire26 days ago

    Atossa Genetics Completes all Dosing and Clinical Visits in its Phase 1 Study of Topical Endoxifen in Men

    Atossa Genetics Inc. (ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that it has completed dosing and clinical visits in its Phase 1 study of its proprietary topical Endoxifen in men. “We are now proceeding to the final stages of this study, which are to complete analysis of blood samples and then collect and analyze the data,” commented Steve Quay, Ph.D., M.D., President and CEO of Atossa. Atossa is developing topical Endoxifen for a condition in men called gynecomastia, which is male breast enlargement.

  • GlobeNewswirelast month

    Atossa Genetics Appoints Two Additional Prominent Industry Executives to Strategic Advisory Board

    Atossa Genetics Inc. (ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced the appointment of two additional pharmaceutical executives to its strategic advisory board. The board will play a key role in a number of important strategic initiatives in accelerating the clinical development of Atossa’s programs. The company has named former Pfizer executive, Dr. Makarand (Mak) Jawadekar and Dr. Ajit Shetty, Chairman of the Belgium-based Flemish Institute of Biotechnology and former Janssen Pharmaceutica NV executive, to Atossa’s strategic advisory board.

  • Does Atossa Genetics Inc’s (NASDAQ:ATOS) -89.06% Earnings Drop Reflect A Longer Term Trend?
    Simply Wall St.last month

    Does Atossa Genetics Inc’s (NASDAQ:ATOS) -89.06% Earnings Drop Reflect A Longer Term Trend?

    When Atossa Genetics Inc (NASDAQ:ATOS) announced its most recent earnings (31 March 2018), I did two things: looked at its past earnings track record, then look at what is happeningRead More...

  • ACCESSWIRE2 months ago

    "The Balancing Act"

    SAN FRANCISCO, CA / ACCESSWIRE / May 31, 2018 / Vista Partners ("Vista") has published May's FREE Macroeconomic & Investment Monthly Newsletter titled "The Balancing Act." Vista's monthly ...

  • GlobeNewswire2 months ago

    Atossa Announces $13.4 Million in Expected Gross Proceeds from Recently Expired Rights Offering

    Atossa Genetics Inc. ("Atossa" or "the Company") announced today that the Company’s previously announced rights offering (“the Rights Offering”) expired on Thursday, May 24, 2018 and these rights are no longer exercisable. The Company accepted all valid subscriptions that were presented and estimates that the Rights Offering will result in approximately $13.4 million in gross proceeds. The results of the Rights Offering and Atossa’s estimates regarding the aggregate gross proceeds of the Rights Offering to be received by Atossa are subject to finalization and verification by Atossa and its subscription agent.

  • When Should You Buy Atossa Genetics Inc (NASDAQ:ATOS)?
    Simply Wall St.2 months ago

    When Should You Buy Atossa Genetics Inc (NASDAQ:ATOS)?

    Atossa Genetics Inc (NASDAQ:ATOS), a medical equipment company based in United States, saw a decent share price growth in the teens level on the NasdaqCM over the last few months.Read More...

  • GlobeNewswire2 months ago

    Atossa Genetics Receives Positive Interim Safety Review from Independent Safety Committee in Phase 1 Topical Endoxifen Dose Escalation Study in Men

    Atossa Genetics Inc. (ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that it has received a second positive interim safety review on its Phase 1 study of topical Endoxifen in men, which is being developed to address gynecomastia (or male breast enlargement), a common condition in patients being treated for prostate cancer. Dr. Steven Quay, Ph.D., MD, President and CEO of Atossa commented, "We can now advance to the next level of the study which is to escalate the dosage in the third and final cohort of subjects as we continue to monitor safety and tolerability in the first and second cohorts of the study.

  • GlobeNewswire2 months ago

    Atossa Genetics To Host Corporate Conference Call Wednesday, May 16, 2018 at 4:30pm EDT

    Atossa Genetics Inc. (ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced it will host a corporate conference call to discuss the Company’s business on Wednesday, May 16, 2018 at 4:30 EDT. For more information, please visit www.atossagenetics.com.

  • GlobeNewswire2 months ago

    Atossa Genetics Announces First Quarter 2018 Financial Results And Provides Company Update

    SEATTLE, May 14, 2018-- Atossa Genetics Inc., a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced ...

  • GlobeNewswire2 months ago

    Atossa Genetics Supports National Women's Health Week Lead by U.S. Department of Health and Human Services’ Office on Women’s Health

    Atossa Genetics Inc. (ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced its support of the 19th Annual National Women’s Health Week lead by the U.S. Department of Health and Human Services’ (HHS) Office on Women’s Health. “As a leading clinical-stage company developing treatment options for breast cancer, we also encourage women to make their health a priority. Managing cardiovascular risks and preventing cancers with screening tests, like the cervical Pap smear and the breast mammogram, are important steps for a long and healthy life,” said Janet R Rea, MSPH, RAC, SVP of Regulatory, Quality and Clinical Affairs for Atossa.

  • GlobeNewswire2 months ago

    Atossa Genetics Regains NASDAQ Compliance

    Atossa Genetics Inc. (ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that it has received notice from NASDAQ that Atossa has regained compliance with NASDAQ minimum closing bid price listing rule 5550(a)(2). Atossa has received notice from NASDAQ stating, in part, that the "Staff has determined that for the last 10 consecutive business days, from April 20 to May 3, the closing bid price of the Company's common stock has been at $1.00 per share or greater.

  • GlobeNewswire2 months ago

    Atossa Genetics Reminds Investors of Today’s Deadline to be a Shareholder of Record

    Atossa Genetics Inc. (ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today issued a reminder to shareholders that the record date for its proposed rights offering is May 9, 2018.  To be a shareholder of record, Atossa stock must be purchased by market close on May 7, 2018 to account for two-day settlement. Under the proposed rights offering, Atossa will distribute one non-transferable subscription right for each share of common stock held on the record date.  Each right will entitle the holder to purchase one unit, at a subscription price of $1,000 per unit, consisting of one share of Series B Convertible Preferred Stock with a face value of $1,000 (and immediately convertible into 284 shares of common stock at a conversion price of $3.52 per share) and 284 warrants with an exercise price of $4.05.  The warrants will be exercisable for 4 years after the date of issuance.

  • GlobeNewswire2 months ago

    Atossa Genetics Forms Strategic Advisory Board to Accelerate Growth

    Atossa Genetics Inc. (ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced the formation of a strategic advisory board comprised of prominent executives from the pharmaceutical industry. The company has named former Pfizer executive, bestselling author and thought leader, Bob Miglani, and Dr. Joseph M. Chalil, formerly an executive at Boehringer Ingelheim, to the strategic advisory board.

  • ACCESSWIRE2 months ago

    Today’s Research Reports on Stocks to Watch: Atossa Genetics and SteadyMed

    NEW YORK, NY / ACCESSWIRE / May 1, 2018 / Pharma stocks Atossa Genetics and SteadyMed were seeing big gains in Monday trading after each company announced big news. Atossa has received approval from the ...

  • GlobeNewswire3 months ago

    Atossa Genetics Receives Approval from the Swedish Medical Products Agency for Phase 2 Topical Endoxifen Study

    SEATTLE, April 30, 2018-- Atossa Genetics Inc., a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, announced ...

  • ACCESSWIRE3 months ago

    "U.S. Economy Remains Strong, Anticipating Steady Growth with Rate Twist"

    SAN FRANCISCO, CA / ACCESSWIRE / April 26, 2018 / Vista Partners ("Vista") has published April's FREE Macroeconomic & Investment Monthly Newsletter, "U.S. Economy Remains Strong, Anticipating ...

  • GlobeNewswire3 months ago

    Atossa Genetics Receives Positive Interim Review from Independent Safety Committee in Phase 1 Topical Endoxifen Dose Escalation Study in Men

    Atossa Genetics Inc. (ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that it has received a positive interim review on its Phase 1 study of topical endoxifen in men, which is being developed to address gynecomastia (or male breast enlargement), which is a common condition in patients being treated for prostate cancer. The Independent Safety Committee reviewed the blinded data generated from the first group in the study (eight subjects) and concluded that the study may advance to the next dosing level. "This positive safety determination is on the critical path for a successful outcome of this Phase 1 study in men," stated Dr. Steven Quay, Ph.D., MD, President and CEO of Atossa.

  • GlobeNewswire3 months ago

    Atossa Genetics Informs Stockholders of Key Dates and Terms Related to Announced Rights Offering

    SEATTLE, April 23, 2018-- Atossa Genetics Inc., a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today provided ...

  • GlobeNewswire3 months ago

    Atossa Genetics Announces 1 for 12 Reverse Stock Split

    SEATTLE, April 20, 2018-- Atossa Genetics Inc., a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced ...